^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Topoisomerase II inhibitor

Related drugs:
19h
Evaluation of some proinflammatory cytokines and biochemical parameters in pre and postmenopausal breast cancer women. (PubMed, Cytokine)
The aims of this study to investigate the evaluation of chemotherapy effects especially doxorubicin and cyclophosphamide only use in this study in pre and postmenopausal breast cancer women on proinflammatory cytokines(IL-6, TNF-α) with CRP and on biochemical parameters(E2, D3, LDH, GGT, TSB, Ca, Ph, uric acid) in pre and postmenapausal breast cancer women. The results of proinflammatory cytokines of and biochemical parameters in premenopausal groups were as the levels of IL-6 (pg/ml),TNF-α(pg/ml) and CRP (ng/ml) showed significant increase differences (P  0.05).
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
|
doxorubicin hydrochloride • cyclophosphamide
1d
Beneficial Effects of Oral Carbon Monoxide on Doxorubicin-Induced Cardiotoxicity. (PubMed, J Am Heart Assoc)
These findings strongly support using HBI-002 as a cardioprotective agent that maintains the therapeutic benefits of doxorubicin cancer treatment while mitigating cardiac damage.
Journal
|
HMOX1 (Heme Oxygenase 1)
|
HMOX1 expression
|
doxorubicin hydrochloride
2d
Pharmacological p38 MAPK inhibitor SB203580 enhances AML stem cell line KG1a chemosensitivity to daunorubicin by promoting late apoptosis, cell growth arrest in S-phase, and miR-328-3p upregulation. (PubMed, Saudi Pharm J)
Remarkably, the enhanced KG1a cell sensitivity to DNR after SB203580 pretreatment was associated with an increased upregulation of miR-328-3p and slight downregulation of miR-26b-5p, compared to DNR effect. Altogether, these findings could contribute to the development of a new therapeutic strategy by targeting the p38 MAPK pathway to improve treatment outcomes in patients with refractory or relapsed AML.
Preclinical • Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • CASP7 (Caspase 7) • MIR328 (MicroRNA 328) • CCNB1 (Cyclin B1)
|
BCL2 expression • TP53 expression
|
daunorubicin
2d
VITAL: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia (clinicaltrials.gov)
P2, N=42, Active, not recruiting, Vanderbilt-Ingram Cancer Center | Trial completion date: Apr 2024 --> Sep 2024
Trial completion date • Combination therapy • Tumor mutational burden
|
SRC (SRC Proto-Oncogene)
|
cytarabine • Qinprezo (vosaroxin) • Starasid (cytarabine ocfosfate)
2d
Apoptotic effect of 5-fluorouracil-doxorubicin combination on colorectal cancer cell monolayers and spheroids. (PubMed, Mol Biol Rep)
The results indicated that the 5-FU + DOX combination therapy induces apoptosis and renders 5-FU and DOX more effective at lower concentrations compared to their alone use. This study reveals promising results in reducing the potential side effects of treatment by enabling the use of lower drug doses.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
|
5-fluorouracil • doxorubicin hydrochloride
2d
Oncogenic functions and therapeutic potentials of targeted inhibition of SMARCAL1 in small cell lung cancer. (PubMed, Cancer Lett)
Pixantrone caused DNA damage and exhibited inhibitory effects on SCLC cells in vitro and in a patient-derived xenograft mouse model. These results indicated that SMARCAL1 functions as an oncogene in SCLC, and pixantrone as a SMARCAL1 inhibitor bears therapeutic potentials in this deadly disease.
Journal
|
SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
|
Pixuvri (pixantrone)
2d
Inhibition of the transmembrane transporter ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of HCC. (PubMed, Hepatol Commun)
The inhibitory effects of doxorubicin treatment and hypoxia on HCCO proliferation are variable, suggesting an important role of tumor-cell intrinsic properties in doxorubicin resistance. ABCB1 is a determinant of doxorubicin response in HCCOs. Combination treatment of doxorubicin and ABCB1 inhibition may increase the response rate to transarterial chemoembolization.
Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1)
|
doxorubicin hydrochloride
2d
Hepatic IRE1α-XBP1 signaling promotes GDF15-mediated anorexia and body weight loss in chemotherapy. (PubMed, J Exp Med)
Here, we report that hepatic GDF15 plays a crucial role in regulating body weight in response to chemo drugs cisplatin and doxorubicin. Genetic and pharmacological inactivation of IRE1α is sufficient to ameliorate chemotherapy-induced anorexia and body weight loss. These results identify hepatic IRE1α as a molecular driver of GDF15-mediated anorexia and suggest that blocking IRE1α RNase activity offers a therapeutic strategy to alleviate the adverse anorexia effects in chemotherapy.
Journal
|
GDF15 (Growth differentiation factor 15) • XBP1 (X-box-binding protein 1)
|
GDF15 elevation
|
cisplatin • doxorubicin hydrochloride
3d
Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov)
P1, N=35, Completed, Washington University School of Medicine | Active, not recruiting --> Completed
Trial completion
|
azacitidine • Qinprezo (vosaroxin)
3d
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib (clinicaltrials.gov)
P2, N=30, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
Trial completion date • Trial primary completion date • Metastases
|
sorafenib • doxorubicin hydrochloride
5d
Changes in blood metabolomes as potential markers for severity and prognosis in doxorubicin-induced cardiotoxicity: a study in HER2-positive and HER2-negative breast cancer patients. (PubMed, J Transl Med)
The changes in blood metabolomes following doxorubicin treatment were dependent on HER2 status, and these changes might serve as severity and prognostic markers of doxorubicin-induced cardiotoxicity.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative
|
doxorubicin hydrochloride
6d
Assessment of the in Vitro Effects of Folate Core-Shell Conjugated Iron Oxide Nanoparticles as a Potential Agent for Acute Leukemia Treatment. (PubMed, Front Biosci (Landmark Ed))
Our study documents the successful synthetization and characterization of iron oxide, which has excellent anticancer activities. A metal oxide conjugation with the nanoparticles' core-shell enhanced the effect against acute leukemia.
Preclinical • Journal • IO biomarker
|
BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
|
doxorubicin hydrochloride
7d
Nano-inducer of ferroptosis for targeted chemotherapy of human triple negative breast carcinoma. (PubMed, Biomater Adv)
In the present work we have developed a TNBC-specific targeted nano-delivery agent comprising of a cRGD labeled magneto-liposome (T-LMD) co-encapsulated with oleic acid coated iron oxide nanoparticles (MN-OA) and doxorubicin (Dox) in the liposome bilayer and core, respectively...The strategic placement of IONPs in the liposome bilayer of T-LMD facilitates the sensitization of MDA-MB-231 cells to undergo ferroptosis; predominantly via the activation of the iron/lipid metabolism pathway, as validated by use of small molecule ferroptosis inhibitor (ferrostatin-1) and iron chelator (deferoxamine)...Thus, our ferroptosis nano-inducer (T-LMD) can efficiently kill TNBC cells via enhanced LPO and ROS generation leading to membrane damage and consequent release of LDH and HMGB1, induce mitochondrial alterations and enhanced DNA double strand breaks. Altogether, our results suggest significant implications of T-LMD for treatment of TNBC.
Journal
|
HMGB1 (High Mobility Group Box 1)
|
doxorubicin hydrochloride
7d
Preparation and Optimization of MiR-375 Nano-Vector Using Two Novel Chitosan-Coated Nano-Structured Lipid Carriers as Gene Therapy for Hepatocellular Carcinoma. (PubMed, Pharmaceutics)
In contrast, the nano-plexes significantly inhibited cell growth compared to free miR-375 or doxorubicin (DOX), respectively...Collectively, our findings clearly emphasized the multifunctionality of the two CS-coated NSLCs in terms of their enhanced biocompatibility, biostability, conjugation, and transfection efficiency of therapeutic miR-375. Therefore, the NSLCs/miR-375 nano-plexes could serve as a novel and promising therapeutic strategy for HCC.
Journal • Gene therapy
|
MIR375 (MicroRNA 375)
|
doxorubicin hydrochloride
8d
Role of Protein Tyrosine Phosphatase Receptor Type E (PTPRE) in Chemoresistant Retinoblastoma. (PubMed, Int J Mol Sci)
Etoposide-resistant RB cell lines and RB patients display significant higher PTPRE expression levels compared to chemosensitive counterparts and the healthy human retina, respectively...Additionally, PTPRE KD led to altered phosphorylation of protein kinase SGK3 and-dependent on the cell line-AKT and ERK1/2, suggesting potential PTPRE downstream signaling pathways. In summary, these results indicate an oncogenic role of PTPRE in chemoresistant retinoblastoma.
Journal
|
MIR31 (MicroRNA 31)
|
etoposide IV
8d
Effect of Melatonin on Chemoresistance Exhibited by Spheres Derived from Canine Mammary Carcinoma Cells. (PubMed, Animals (Basel))
These results indicate that melatonin negatively modulates the cell survival of spheres derived from CF41.Mg cells, in a way that is independent of its MT1 receptor. These effects did not counteract the resistance to doxorubicin and mitoxantrone, even though the hormone negatively regulates the gene expression of MDR1 and ABCG2.
Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • CD24 (CD24 Molecule)
|
ABCG2 expression
|
doxorubicin hydrochloride • mitoxantrone
8d
Low-Density Lipoproteins Increase Proliferation, Invasion, and Chemoresistance via an Exosome Autocrine Mechanism in MDA-MB-231 Chemoresistant Cells. (PubMed, Biomedicines)
Doxorubicin (Dox) treatment, a member of the anthracycline family, represents a typical therapeutic strategy; however, chemoresistance remains a significant challenge...Moreover, the specific down-regulated profile of chaperones Hsp90 and Hsp70 secretion inside the exosomes of the chemoresistant variant could be associated with this phenomenon. Therefore, autocrine activation mediated by exosomes and the effect of LDL internalization may influence changes in exosome chaperone content and modulate proliferative signaling pathways, increasing the aggressiveness of MDA-MB-231 chemoresistant cells.
Journal
|
EIF4G1 (Eukaryotic translation initiation factor 4 gamma, 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
|
doxorubicin hydrochloride
8d
Uncovering the Cardioprotective Potential of Diacerein in Doxorubicin Cardiotoxicity: Mitigating Ferritinophagy-Mediated Ferroptosis via Upregulating NRF2/SLC7A11/GPX4 Axis. (PubMed, Antioxidants (Basel))
In conclusion, for the first time, our findings validated DCN's cardioprotective potency against DIC based on its antioxidant, anti-inflammatory, anti-ferroptotic, and anti-apoptotic imprint, chiefly mediated by the NRF2/SLC7A11/GPX4 axis. Accordingly, DCN could represent a promising therapeutic avenue for patients under DOX-dependent chemotherapy.
Journal
|
GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11)
|
doxorubicin hydrochloride
8d
Effect of Transarterial Chemotherapy on the Structure and Function of Gut Microbiota in New Zealand White Rabbits. (PubMed, Biology (Basel))
Following transarterial chemotherapy with epirubicin, the Firmicutes abundance decreased, whereas that of Proteobacteria increased...Hepatic arterial chemotherapy induces dysbiosis of the intestinal microbiota, disrupts intestinal barrier function, damages the integrity of the intestinal mucosa, increases intestinal permeability, facilitates excessive passage of harmful substances through the gut-liver axis communication between the liver and intestine, and triggers activation of inflammatory pathways such as LPS-TLR-4-pSTAT3, ultimately leading to an inflammatory response. This study provides a theoretical basis for combining TACE with targeted GM intervention to treat HCC and reduce adverse gastrointestinal reactions.
Preclinical • Journal
|
TLR4 (Toll Like Receptor 4)
|
epirubicin
9d
Nitrogen-containing andrographolide derivatives with multidrug resistance reversal effects in cancer cells. (PubMed, RSC Med Chem)
Moreover, all selected compounds displayed synergistic interaction with doxorubicin, with compound 3 being the most active. In the ATPase assay, selected compounds exhibited characteristics of P-gp inhibitors.
Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1)
|
doxorubicin hydrochloride
9d
PROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis. (PubMed, BMC Cancer)
The SCLC-LM model effectively simulates the pathophysiological process of SCLC metastasis to the leptomeninges. PROTAC EZH2 degrader-1 overcomes chemoresistance in SCLC, suggesting its potential therapeutic value for SCLC LM.
Journal
|
SLC44A4 (Solute Carrier Family 44 Member 4) • SLC4A4 (Solute carrier family 4 member 4) • DERL1 (Derlin 1)
|
cisplatin • etoposide IV • Vumon (teniposide)
9d
Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML (clinicaltrials.gov)
P=N/A, N=37, Not yet recruiting, First Affiliated Hospital Xi'an Jiaotong University
New trial
|
fludarabine IV • thiotepa • busulfan • Duoenda (mitoxantrone liposomal)
9d
siRNA treatment targeting integrin α11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression. (PubMed, Breast Cancer Res)
Our findings elucidate that integrin α11 is upregulated by EZH2, forming a positive feedback circuit involving FAK-GLI-1 and contributing to drug resistance, cancer stem cell survival and EMT. Taken together, the results suggest integrin α11 as a promising prognostic marker and a powerful therapeutic target for drug-resistant breast cancer.
Journal
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
EZH2 overexpression • HIF1A expression • EZH2 positive
|
tamoxifen • doxorubicin hydrochloride
10d
Safety and biologic activity of a canine anti-CD20 monoclonal antibody in dogs with diffuse large B-cell lymphoma. (PubMed, J Vet Intern Med)
The canine 1E4-cIgGB anti-CD20 monoclonal antibody is apparently safe when administered with doxorubicin and effectively depletes B-cells in dogs with DLBCL.
Journal
|
CD5 (CD5 Molecule)
|
doxorubicin hydrochloride
10d
Crocin, the compound of the dried stigma of Crocus sativus L (saffron), restores doxorubicin-induced disturbances in kidney functioning, oxidative stress, inflammation, renal tissue morphology and TGF-β signalling pathways. (PubMed, Nat Prod Res)
Our results were confirmed by immunohistochemical findings that Cr treatment ameliorates the expressions of IL1β and TGF-β in Dox-induced nephrotoxicity. Conclusionally, Cr exhibits adequate nephroprotective effects against Dox-induced nephrotoxicity on rat kidney architecture and tissue function by stabilising cellular redox homeostasis, reducing renal fibrosis and suppressing inflammation.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • IL1B (Interleukin 1, beta) • CAT (Catalase)
|
doxorubicin hydrochloride
10d
Reversal Effect of Arctigenin on the Drug Resistance in Leukemia K562/A02 Cells and Its Mechanism (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
ARG may reverse the resistance of human leukemia cell line K562/A02 to ADM by inhibiting TLR4/NF-κB signaling pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • TLR4 (Toll Like Receptor 4)
|
BCL2 expression • BAX expression • TLR4 overexpression
|
doxorubicin hydrochloride
10d
Apigetrin ameliorates doxorubicin prompted testicular damage: biochemical, spermatological and histological based study. (PubMed, Sci Rep)
However, APG supplementation significantly reversed all the testicular damages due to its androgenic, anti-apoptotic, anti-oxidant and anti-inflammatory nature. Therefore, it is concluded that APG may prove a promising therapeutic agent to treat DOX-induced testicular damages.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CAT (Catalase)
|
BAX expression
|
doxorubicin hydrochloride
10d
Wild-type IDH2 is a therapeutic target for triple-negative breast cancer. (PubMed, Nat Commun)
Such metabolic double-hit results in ATP depletion and suppression of tumor growth, and renders TNBC cells more sensitive to doxorubicin treatment. Our study reveals a metabolic property of TNBC cells with active utilization of glutamine via reductive TCA metabolism, and suggests that wild-type IDH2 plays an important role in this metabolic process and could be a potential therapeutic target for TNBC.
Journal
|
IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
IDH wild-type
|
doxorubicin hydrochloride
10d
H2S-driven chemotherapy and mild photothermal therapy induced mitochondrial reprogramming to promote cuproptosis. (PubMed, J Nanobiotechnology)
A multifunctional cascade bioreactor based on the H2S-responsive mesoporous Cu2Cl(OH)3-loaded hypoxic prodrug tirapazamine (TPZ), in which the outer layer was coated with hyaluronic acid (HA) to form TPZ@Cu2Cl(OH)3-HA (TCuH) nanoparticles (NPs), demonstrated a synergistic antitumor effect through combining the H2S-driven cuproptosis and mild photothermal therapy...The enriched Cu2+ induced not only cuproptosis by promoting lipoacylated dihydrolipoamide S-acetyltransferase (DLAT) heteromerization but also performed chemodynamic therapy though catalyzing H2O2 to produce highly toxic hydroxyl radicals ·OH. Therefore, the nanoparticles TCuH offer a versatile platform to exert copper-related synergistic antitumor therapy.
Journal
|
DLAT (Dihydrolipoamide S-Acetyltransferase)
|
Tirazone (tirapazamine)
10d
Discovery of Anti-CD47 Peptides as Innate Immune Checkpoint Inhibitors. (PubMed, Adv Ther (Weinh))
CMP-22 peptide showed the ability to increase the antitumor activity of doxorubicin and extends the survival of CT26 tumor-bearing mice. The discovered anti-CD47 peptides can be considered potential candidates for cancer immunotherapy by blocking the CD47/SIRPα interaction, especially in combination with chemotherapy, to elicit synergistic effects.
Journal • Checkpoint inhibition
|
CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
|
CD47 expression
|
doxorubicin hydrochloride
11d
Combination Therapy for Recurrent Ovarian Cancer (clinicaltrials.gov)
P1/2, N=72, Recruiting, Sham Sunder Kakar | Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2025 --> Nov 2026
Enrollment open • Trial primary completion date • Combination therapy
|
MUC16 (Mucin 16, Cell Surface Associated)
|
MUC16 elevation
|
pegylated liposomal doxorubicin
11d
Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/PD-L1 signaling. (PubMed, J Exp Clin Cancer Res)
Our results highlight CXCL1EV-dead as a novel dying cell-released signal and provide TPCA-1 as a targeting candidate to improve TNBC prognosis.
Journal
|
PD-L1 (Programmed death ligand 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
|
paclitaxel • doxorubicin hydrochloride
11d
Betaine ameliorates doxorubicin-induced cardiomyopathy by inhibiting oxidative stress, inflammation, and fibrosis through the modulation of AMPK/Nrf2/TGF-β expression. (PubMed, Environ Toxicol)
Here, we provide the first evidence that betaine treatment prevents DOX-induced cardiomyopathy by inhibiting oxidative stress, inflammation, and fibrosis by regulating AMPK/Nrf2/TGF-β expression. We believe that betaine can be utilized as a potential novel therapeutic strategy for preventing DOX-induced cardiotoxicity.
Journal
|
TP53 (Tumor protein P53) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • ACTA2 (Actin Alpha 2 Smooth Muscle) • TGFB1 (Transforming Growth Factor Beta 1) • NLRP3 (NLR Family Pyrin Domain Containing 3) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • CAT (Catalase)
|
TP53 expression
|
doxorubicin hydrochloride
11d
Novel PLGA-based nanoformulation decreases doxorubicin-induced cardiotoxicity. (PubMed, Nanoscale)
Nanotechnology has the potential to provide formulations of antitumor agents with increased selectivity towards cancer tissue thereby decreasing systemic toxicity. In the case of LipoDOX, autophagy and apoptosis were still detectable, whereas PLGADOX induced only detectable mitochondrial toxicity. Cardiotoxic effects were frequently sex-related with the greater risk of cardiotoxicity observed mostly in male rats.
Journal
|
IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8)
|
CXCL8 expression • IL6 expression
|
doxorubicin hydrochloride • pegylated liposomal doxorubicin
12d
Protective effects of arbutin against doxorubicin-induced cardiac damage. (PubMed, Mol Biol Rep)
The study suggests that arbutin has the potential to be used to mitigate doxorubicin-induced cardiotoxicity in cancer patients.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta) • CAT (Catalase)
|
doxorubicin hydrochloride
12d
Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant (clinicaltrials.gov)
P2, N=308, Active, not recruiting, Henry Ford Health System | Trial completion date: Apr 2024 --> Aug 2024 | Trial primary completion date: Apr 2024 --> Aug 2024
Trial completion date • Trial primary completion date
12d
Promising anticancer activity of cromolyn in colon cancer: in vitro and in vivo analysis. (PubMed, J Cancer Res Clin Oncol)
Our study showed that cromolyn is a selective and strong drug in inhibiting the proliferation of colon cancer cells. Based on our results, the efficacy of C in vitro analysis (MTT assays and apoptosis), as well as animal studies is competitive with the FDA-approved drug doxorubicin. C is very promising as a low-complication and good-efficacy drug for cancer drug repositioning. This requires clinical research study designs to comprehensively evaluate its anti-cancer effects.
Preclinical • Journal
|
ANXA5 (Annexin A5)
|
doxorubicin hydrochloride
12d
Inhibition of CDK7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy. (PubMed, Cardiovasc Res)
Activation of CDK7 is necessary for DOX-induced cardiomyocyte apoptosis and cardiomyopathy. Our findings uncover a novel proapoptotic role for CDK7 in cardiomyocytes. Moreover, this study suggests that inhibition of CDK7 attenuates DOX-induced cardiotoxicity, but augments the anticancer efficacy of DOX. Therefore, combined administration of CDK7 inhibitor and DOX may exhibit diminished cardiotoxicity but superior anticancer activity.
Journal
|
CDK7 (Cyclin Dependent Kinase 7)
|
doxorubicin hydrochloride
13d
Evaluate the in vitro effect of anthracycline and alkylating cytophosphane chemotherapeutics on dopaminergic neurons. (PubMed, Cancer Rep (Hoboken))
This is one of the first reports that reveal Doxorubicin and Cyclophosphamide induce significant dopaminergic neurotoxicity. Thus, Chemotherapy-induced adverse drug reaction issues substantially persist during and after treatment and sometimes never be completely resolved clinically. Consequently, failure to adopt adequate patient care measures for cancer patients treated with certain chemotherapeutics might substantially raise the incidence of numerous movement disorders.
Preclinical • Journal
|
BAX (BCL2-associated X protein)
|
BAX expression
|
doxorubicin hydrochloride • cyclophosphamide
14d
PYCR3 Modulates mtDNA Copy Number to Drive Proliferation and Doxorubicin Resistance in Triple-Negative Breast Cancer. (PubMed, Int J Biochem Cell Biol)
Thus, our study underscores the clinical relevance of PYCR3 and highlight its potential as a therapeutic target in TNBC management. By elucidating the functional significance of PYCR3 in TNBC, our findings contribute to a deeper understanding of TNBC biology and provide a foundation for developing novel therapeutic strategies aimed at improving patient outcomes.
Journal
|
PRO-C3 (Pyrroline-5-carboxylate reductase)
|
doxorubicin hydrochloride
14d
Electrocardiographic, biochemical, and scintigraphic evidence for the cardioprotective effect of paricalcitol and vitamin D3 on doxorubicin-induced acute cardiotoxicity in rats. (PubMed, Bratisl Lek Listy)
Results show that vitamin D receptor agonist paricalcitol and vitamin D protect against DX-induced cardiotoxicity through anti-inflammatory and antioxidant effects (Fig. 4, Ref. 59). Text in PDF www.elis.sk Keywords: paricalcitol, doxorubicin, vitamin D, ECG, 99mTc-PYP scintigraphy, cardiotoxicity, inflammation.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
|
doxorubicin hydrochloride
15d
Intelligent Biogenic Missile for Two-Photon Fluorescence Imaging-Guided Combined Photodynamic Therapy and Chemotherapy in Tumors. (PubMed, Anal Chem)
Additionally, this intelligent biogenic missile enables the controlled release of doxorubicin (DOX). The innovative strategy substantially enhances the targeted therapeutic effectiveness of cancer cells. The intelligent biogenic missile provides an effective method for the early detection and treatment of tumors, which has a good application prospect in the real-time high-sensitivity diagnosis and treatment of tumors.
Journal
|
PTK7 (Protein Tyrosine Kinase 7)
|
doxorubicin hydrochloride